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M ORE than two decades ago, Laurel! and Erickson' recognized the association 
between familial pulmonary emphysema and 
alpha-I-antitrypsin deficiency (AIAD). Sub-
sequently, Freier et ae and Sharp et ae 
described the first children with AIAD and 
liver disease. This association has also been 
described in adults.4•5 
No specific medical therapy exists for 
AIAD patients who develop liver disease.6.7 
Furthermore, although portal-systemic shunt 
procedures have been performed in such 
patients in an attempt to prevent the develop-
ment of progressive liver disease,s such proce-
dures have not improved liver function or 
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quality of life and have not enhanced the 
long-term survival when cirrhosis is already 
established. Currently orthotopic liver trans-
plantation (OL T) appears to be the best 
option available to these patients. The purpose 
of this report is to present our experience with 
OLT in patients with AIAD and advanced 
liver disease. 
PATIENTS AND METHODS 
Patient Population 
Five hundred and sixty-two patients underwent hepatic 
transplantation between March I, 1980 and February 28, 
1986 at the University of Pittsburgh Health Center. 
Three hundred and thirty-nine patients were adults, and 
223 were children (<18 years of age). Thirty nine of these 
(29 children, 10 adults) had end-stage liver disease due to 
AIAD. In each case the diagnosis of AIAD was estab-
lished by measurement of the AlA level in serum and 
determination of the specific Pi type of each. Moreover, 
histologic confirmation of classic A 1 AD liver disease was 
available from liver biopsy samples obtained in 27 
patients preoperatively and from the excised liver speci-
men in all 39. The pediatric patients ranged in age from 8 
months to 13 years, with a mean of 5 years. The adult 
patients ranged in age from 18 to 48 years, with a mean of 
34 years. 
The basic immunosuppressive regimen used consisted 
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Table 1. Preoperative Phenotype and A 1 A Enzyme Activity of 39 Liver Transplant Recipients 
Children 
No. of Serum AlA mg/dL' 
Patients Phenotype Mean Range 
22 (76%) PiZZ 43.3 (0.4-80) 
2 (7%) PiSZ 121.5 (38.2-285) 
2 (7%) PiMZ 121.5 (38.2-285) 
3 (10%) Unknown Unknown 
n - 29 
*Normal - 85.0 to 213 mg/dL. 
of cyclosporine (Cs) and prednisone." Since December 
1983 OKT3 (Orthoclone; ORTHO Pharmaceuticals, 
Raritan, N J) has been used for the treatment of acute 
rejection episodes resistant to conventional immunosup-
pression therapy.'o 
All data are presented as mean values and range. 
Patient survival was calculated by the life table method 
(MOP, statistical software, Los Angeles, CA). 
RESULTS 
Pediatric Patients 
The clinical features present in the 29 chil-
dren herein reported led to the diagnosis of 
AIAD with the presence of neonatal cholesta-
sis in 23, ascites in three, and portal hyperten-
sion with gastrointestinal (G I) bleeding in 
three patients. The mean patient age at the 
time of diagnosis was 11 months, with a range 
of I month to 6 years. A summary of the AlA 
phenotype data and serum levels of AlA in 
these individuals is presented in Table 1. At 
the time of the initial diagnosis, liver biopsies 
obtained from these children demonstrated 
diastase-resistant intracytoplasmic eosino-
philic bodies that reacted with periodic acid-
Schiff (PAS) stains in 22 patients, cirrhosis in 
17 patients, and hepatic fibrosis in four 
patients. Four patients who had PiZZ pheno-
type had emphysema. Two of these children 
Table 2. Clinical Features at the Time of Ol T 
Pediatric Group Adult Group 
(n - 29) (n - 10) 
No. of Patients No. of Patients 
Ascites 23 (79%) 8(80%) 
GI bleeding 17 (59%) 8(80%) 
Jaundice 11 (38%) 2 (20%) 
Encephalopathy 3 (10%) 4(40%) 
Adults 
Serum AlA mg/dL' 
Patients Phenotype Mean Range 
8(80%) Pill 28.3 (12-45) 
2(20%) PiMZ 90.0 (70-115) 
n - 10 
had been treated with a creation of portal 
systemic shunts, and one child with associated 
extrahepatic biliary atresia had had two por-
toenterostomy procedures (Kasai) prior to 
liver transplantation. The dominant clinical 
features at the time of OLT in these 29 
children are shown in Table 2. 
At the time of data collection 24 out of 29 
pediatric patients were discharged from the 
hospital and were alive, with a follow-up rang-
ing from 8 to 60 months (mean 26 months). 
The actuarial survival at 5 years is 83% (Fig 
1). Six patients (20%) required a second he-
patic allograft, and the indications for the 
second transplant procedures are listed in 
Table 3. Five patients (17%) died during the 
first 3 postoperative months. Vascular compli-
cations were responsible for the death of two, 
and each death actually occurred after 
retransplantation. One of these two patients 
had a ruptured mycotic aneurysm involving a 
donor iliac artery graft that had been used for 
the arterial reconstruction. The causes of 
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Fig 1 . Actuarial survival curve in adult and pediatric 
liver recipients after hepatic transplantation for A1AD. 
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Table 3. Major Complications and Indications for Liver 
Retransplantation in A 1 AD Pediatric Recipients 
Vascular Complications 
Hepatic artery throm bosis 
Portal vein and vena cava 
thrombosis 
Thrombosis of hepatic artery and 
vena cava 
Biliary Complications 
Biliary leak 
Biliary stricture 
Miscellaneous 
Primary allograft nonfunction 
Varicella pneumonitis 
Chronic rejection 
Intraabdominal abscess 
Postoperative hemorrhage 
Small bowel obstruction 
Patients Re Tx Deaths 
3 
3 
2 
2 
1* 
1 
o 
o 
o 
o 
2 
o 
o 
o 
o 
1 
o 
o 
o 
'This patient had thrombosis of the hepatic artery; there-
fore it is also included under vascular complications. 
death in the other three patients were primary 
graft nonfunction, varicella pneumonitis, and 
shock due to small bowel obstruction. Biliary 
complications occurred in five. Three devel-
oped biliary leaks, and in two of these three 
the cause of the biliary leak was thought to be 
thrombosis of the hepatic artery with duct 
ischemic injury. Two patients developed bil-
iary strictures thought to be the result of 
thrombosis of the hepatic artery in one and 
rejection in the other. Other major complica-
tions present in these patients are listed in 
Table 3. 
Twenty-two of the 24 surviving children 
have normal hepatic function. One child 
developed lymphoproliferative disease involv-
ing the cervical nodes 1 year posttransplanta-
tion and was managed successfully by reduc-
ing the immunosuppression. At the present 
time this child is free of recurrence 20 months 
later. The child who had associated extrahe-
patic biliary atresia currently has an obstruc-
tion of the common bile duct at the confluence 
of the hepatic ducts, which occurred as a 
result of thrombosis of the hepatic artery. His 
biliary tree is being drained via a percuta-
neous catheter. Although his transaminase 
levels are twice the upper limit of normal, he 
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remains free of biochemical jaundice. More-
over, he is growing well and is free of sepsis. 
Another child has advanced chronic rejection 
and currently is awaiting retransplantation. 
All children of school age are attending 
school. 
Adult Patients 
The presenting symptoms at the time of 
initial diagnosis of AIAD in the ten patients 
reported were GI bleeding in four, ascites in 
four. and jaundice in two patients. The pheno-
type and the A 1 A activity of these ten individ-
uals are shown in Table 1. Liver histology at 
the time of initial diagnosis was cirrhosis in 
five. Diastase-resis tan t - P AS-posi ti ve intracy-
toplasmic eosinophilic bodies were identified 
in the liver tissue of all patients. Two of these 
ten adults were diagnosed as having AIAD 
early in childhood. Omitting these two 
patients, the mean time interval between the 
onset of symptoms of liver disease and OLT 
was 3 years, with a range of 1 to 9 years. Only 
one of these adult patients who was pheno-
typed as PiZZ had chronic obstructive pulmo-
nary disease. Three of these ten adult patients 
had portosystemic shunts performed prior to 
transplantation. The clinical features at the 
time of transplantation are presented in Table 
2. 
Six of the ten adult patients are alive, with a 
projected 5-year survival of 60%. The four 
patients who died did so within 6 months of 
OL T. The causes of death in these four 
patients were listeria and pseudomonas septi-
cemia (one case), intracerebral hemorrhage 
(one case), pneumocystis pneumonitis (one 
case). and viral and fungal sepsis occurring in 
a setting of hepatic artery thrombosis (one 
case). Two of these adult patients required 
retransplantation for hepatic artery thrombo-
sis and for primary graft nonfunction and 
rejection (two grafts) in the other patient. 
Nine major complications occurred in five 
patients, and only one of these patients sur-
vived (Table 4). None of the other patients 
had postoperative complications. 
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Table 4. Major Postoperative Complications in Five 
A 1 AD liver Recipient Patients 
Listeria and pseudomonas septicemia 
Bleeding duodenal ulcer 
Thrombosis of the hepatic artery 
Primary graft nonfunction 
Chronic rejection 
Cytomegalovirus hepatitis 
Intracerebral hemorrhage 
Intraabdominal hemorrhage 
Biliary leak 
All six surviving adult patients currently 
have normal graft function. They are all work-
ing full time, and one recently delivered a 
healthy child. It should be noted that one of 
the adults had an incidental hepatoma at the 
time of OL T and is still alive and well with no 
evidence of recurrence 5 years after OLT. 
DISCUSSION 
Ten percent to 20% of the PiZZ children 
develop advanced histologic liver disease if 
neonatal hepatitis is present in the first 
months of life. 11 •12 Some children with Al AD 
have no clinical evidence of the liver disease 
except for abnormal liver injury tests early in 
lifeY A few adults (12%) with severe AIAD 
PiZZ also develop liver cirrhosis, and the risk 
increases in patients over the age of 50.13 
It has been stated that approximately 40% 
of a normal AlA level is necessary to avoid 
liver damage14; however, in the present study 
two heterozygous adults (PiSZ, PiMZ) had 
normal values of the A1AD. These two indi-
viduals had histopathologic confirmation of 
their AIAD (presence of the intracytoplasmic 
eosinophilic bodies that were PAS positive 
and diastase resistant). These would appear to 
support the theory that the liver disease of 
AIAD is related to the retention of intracellu-
lar PAS-positive-diastase-resistant globules 
of AlA protein within hepatocytes rather 
than the AIAD per se. 
Liver cirrhosis associated to A1AD carries 
a fatal prognosis. The evolution is typical, 
with progressive deterioration leading to 
death due to progressive hepatocellular failure 
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or hemorrhage occurring as a result of severe 
portal hypertension.15•16 Liver transplantation 
provides metabolic cure manifested by (I) 
acquisition of the phenotype of the donor, (2) 
normalization in the serum AlA level, (3) 
elimination of the liver disease, and, presum-
ably, (4) prevention of the complications asso-
ciated with PiZZ, such as pulmonary dis-
ease. 17•18 The appropriate timing for trans-
plantation in these patients is when signs of 
hepatic failure or decompensation begin to 
appear. 
Long-term survival should not be the only 
parameter used to assess the results of liver 
transplantation. The quality of life of trans-
plant recipients is also important and is proba-
bly the most important of the two parameters 
used to justify OLT. In the present series the 
majority of the patients transplanted enjoy a 
lifestyle identical to that of normal people. 
Liver replacement has given these patients a 
definitive metabolic cure with a chance for an 
excellent rehabilitation and long-term surviv-
al. 
SUMMARY 
Thirty-nine patients (29 children and ten 
adults) underwent OLT for liver disease asso-
ciated with A1AD from March 1980 to 
March 1986. Thirty of thirty-six patients 
(83%) with available data were homozygous 
phenotype PiZZo The other six were Pi hetero-
zygotes, being either PiMZ or PiSZ. The 
mean AlA activity in homozygous and het-
erozygous patients was 38.8 mg/dL and 114.3 
mg/dL respectively. Eight patients died dur-
ing the first 3 months after OLT (20%). The 
5-year actuarial survival is 83% and 60% in 
pediatric and adult recipients respectively. 
Today 30 (76%) of the recipients are alive, 
with follow-ups of 8 to 64 months (average 27 
months). The quality of life in the surviving 
patients is excellent. 
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